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Introduction
The terminology oral cancer is interchangeable with 
oral squamous cell carcinoma (OSCC) which is estimated 
to be 90% of all oral neoplasms (Choi and Myers, 2008). 
Oral cancer is considered as one of the chief public health 
issue worldwide, accounting for 2-4% of all cancer cases. 
Despite significant improvements achieved during the 
last decades in its detection, prevention, and treatment; 
outcome and prognosis related to OSCC cure and survival 
is poor due to treatment resistance and tumor recurrence. 
For most countries, age-adjusted death rates have been 
estimated to be 3–4 per 100,000 in men and 1.5–2.0 per 
100,000 for women (Bray et al., 2018). The mortality rate 
is steadily even in the younger generation. The removal 
of two main risk factors: cigarette smoking and alcohol 
consumption can potentially reduce the incidence of 
Abstract
Background: HER-2/neu is a member of the human epidermal growth factor (HER) family of transmembrane 
tyrosine kinases, which is significantly associated with the pathogenesis of various cancer types. The aim was to 
evaluate the expression of HER-2/neu in oral squamous cell carcinoma (OSCC) as a potential biomarker to target 
antigens for specific immunotherapy in OSCC. Methods: One hundred and forty histologically diagnosed OSCC cases 
were identified. Four to five-micrometer thick formalin-fixed, paraffin-embedded tumor sections were stained with 
Haematoxylin and Eosin (H and E). Histological grade was assessed according to WHO/Broders classification, while 
tumors were staged according to the American Joint Committee on Cancer (AJCC) TNM classification from stage I 
to IV. Immunohistochemistry was performed by using Rabbit monoclonal antibody against HER-2/neu (EP700Y, cell 
marquee and diluted 1:50). FISH was performed on positive cases using Vysis PathVysion HER-2 DNA probe (Abbott 
USA). Probes consist of LSI HER gene spectrum orange and control probe CEP 17 spectrum green. Results: In this 
study, males were mostly effected (64.3%) with buccal mucosa (49%) to be the commonly involved site for OSCC. 
Majority of cases were moderately differentiated (62.1%) and 50.7% tumors were Stage IV. HER-2/neu was found to 
be positive (2+) in one case of OSCC, however weak to moderate complete membrane staining was observed in >10% 
of the tumor cells. One hundred and thirty nine cases were HER-2/neu negative. FISH analysis of HER-2/neu positive 
cases also showed gene amplification (Her2-neu/ CEp 17 = 225/33 = 7.2). Conclusions: The study showed disparity 
in the expression of HER-2/neu in OSCC, which is due to multiple reasons. Therefore therapy against HER-2/neu in 
OSCC is debatable.
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oral cancer up to three-quarters (Beynon et al., 2018). 
Regardless of the accessibility of oral cavity for clinical 
examination and advance research into pathogenesis and 
management, the 5-year survival rate for OSCC has not 
improved (Mirza et al., 2016). Many molecular markers 
have been identified reflecting the aggressive behavior 
of OSCC, however none of these markers have shown 
unequivocal prognostic or predictive significance (Sharma 
et al., 2013; Gupta et al., 2016).
The HER-2/neu (ErbB) protein is a tyrosine kinase 
receptor belonging to tyrosine kinase family comprising 
of; erbB1, erbB2, erbB3, and erbB4. These proteins play an 
essential part in cellular growth and differentiation (Mirza 
et al., 2016; Seifi et al., 2009). The dysregulation of these 
receptors, lead to an uncontrolled cell cycle, resistance 
to apoptotic stimuli, invasiveness, chemo-resistance, and 
angiogenesis (Pardis et al., 2012; Salem et al., 2006). 
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Evidence suggests overexpression of HER-2/neu in 
advanced diseases, metastasis-associated with poor clinical 
outcomes in breast and ovarian carcinoma, osteosarcoma; 
endometrial, salivary, and gastric carcinomas (Bonelloet 
al., 2018; Khan et al., 2002; Omar et al., 2015). Research 
studies have correlated the immunohistochemical 
expression of Her-2/neu with a more aggressive behavior 
in breast cancer leading to shorter overall survival. Ramic 
et al., (2013) stated that HER-2/neu is overexpressed in 
approximately 20-25% of cases of invasive breast cancer 
(BC), resulting in tumors with more aggressive biological 
behavior leading to poor prognosis, shorter survival and 
increased risk of death. 
In a study by Ahmed Al Aziz et al., (2017) it was 
concluded that Her2/neu can be used as an independent 
prognostic marker for tumor recurrence after complete 
resection of gastrointestinal stromal tumors. Concerning 
oral squamous cell carcinoma, the biological behavior 
of tumor is highly variable and studies on HER-2/neu 
are discordant and insufficient (Dragomir et al., 2012; 
Kouhsoltani et al., 2015; Schartinger et al., 2009). The 
incidence of Her2/ neu overexpression has ranged from 
0 to 40% (Angiero et al., 2008; Cavalot et al., 2007; 
Sardari et al., 2012). By contrast, Singla et al., (2018) 
reported Her-2/neu expression to be negative, though 
cytoplasmic positivity was observed in a few cases. 
Continued therapeutic developments have resulted in 
targeted therapies against HER-2/neu in the breast, 
gastric and lung carcinomas (Liu et al., 2010; Moelanset 
al., 2011). Bang et al conducted a phase 3, randomized 
controlled trial and concluded that trastuzumab in 
combination with chemotherapy exhibits both efficacy 
and safety for the first-line treatment of advanced gastric 
cancer with expression of HER-2 (Bang et al., 2010). 
In a similar report, Ohashi et al., (2017) reported that 
approximately 5% of NSCLC tumors possess HER2 
alterations, and Trastuzumab emtansine (an anti-HER2 
antibody conjugated with a vinca alkaloid) has shown 
excellent antitumor effects against HER2/neu. The therapy 
targeting this pathway in OSCC could uncover valuable 
evidence, and a clinical trial about this signal would be 
worthy. Therefore, the present study aimed to evaluate the 
expression of HER-2/neu in OSCC to identify a potential 
biomarker, potentially used as a target antigen for specific 
immunotherapy against OSCC.
Materials and Methods
This study included 140 cases of Oral Squamous 
Cell Carcinoma (OSCC) presenting to the maxillofacial 
department of Ziauddin college of Dentistry. The processing 
was performed at Histopathology Laboratory of Ziauddin 
Hospital, Karachi, Pakistan. The clinic-pathologic data 
of each case was collected using a questionnaire. Cases 
without complete clinicopathologic data, inadequate 
paraffin-embedded material, incisional biopsies, and 
recurrent OSCC were excluded. Specimens were routinely 
processed, fixed overnight in 10% buffered formalin 
and were examined grossly according to the standard 
guidelines. Four to five-micrometer thick formalin-fixed, 
paraffin-embedded tumor sections were stained with 
H and E. Histological grade was assessed according to 
WHO/Broders classification (El-Mofty, 2007; Schwab, 
2011). Tumors were staged according to the American 
Joint Committee on Cancer (AJCC) TNM classification 
seventh edition from stage I–IV. The ethics committee 
of Ziauddin University, College of Dentistry, provided 
ethical approval.
Immunohistochemistry evaluation
Immunohistochemistry was performed by using Rabbit 
monoclonal antibody against HER-2/Neu (EP700Y, cell 
marquee and diluted 1:50). The HER-2 protein immune-
expression was analyzed using the American Society of 
Clinical Oncology/College of American Pathologists 
(ASCO/CAP) guidelines for Her-2 testing in Breast 
Cancer, as shown below (Bernardes et al., 2011).
‘0’- no staining or membrane staining is observed in 
< 10% of the tumor cells;
‘1+’- faint/barely perceivable membrane staining is 
detected in > 10% of the tumor cells, and only part of the 
membrane is stained;
‘2+’-weak to moderate complete membrane staining 
is observed in >10% of the tumor cells; 
‘3+’-strong complete membrane staining is observed 
in > 30% of the tumor cells.
Fluorescence in situ hybridization
A 4-5-micron paraffin-embedded tissue section was 
taken on a positively charged slide, the sample was 
pretreated with xylene to remove paraffin and ethanol 
then subjected to proteinase treatment (pepsin) before 
proceeding to apply FISH probe. Vysis PathVysion 
HER-2 DNA probe (Abbott USA) was used. Probes 
consisted of LSI HER gene spectrum orange and control 
probe CEP 17 spectrum green. The probe is applied to the 
slide and placed in thermobrite for denaturation at 73°C 
for 7 minutes and hybridization for 24hrs. Post washing 
was performed after 24hrs with a reagent NP-40 to remove 
the unattached probe and apply Dapi (counterstain). On 
fluorescent microscopy, approximately 20 nuclei were 
counted with a red signal representing the HER-2 gene 
and green signal CEP 17.
Interpretation of FISH
FISH was analyzed using the American Society of 
Clinical Oncology/College of American Pathologists 
(ASCO/CAP) guidelines for Her-2 testing in breast 
cancer as shown below (Richardson et al., 2012; Wolff 
et al., 2007).
Negative (not amplified) - Average Her2 copy number 
< 4.0 signals/ cell.
Equivocal – Average Her2 copy number ≥ 4.0 and < 
6.0 signals/ cell.
Positive (amplified) – Average Her2 copy number ≥ 
6.0 signals/cell.
Statistical analysis
Statistical analysis was performed using the SPSS 
software program (v.21.0 for Windows, IBM, Chicago, 
IL). Data for categorical variables such as age, gender, 
lymph node involvement, site of the primary lesion, 
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Her2/neu in oral cancer has shown wide variation (3-
34%) (Bei et al., 2004; Roberto Bei et al., 2001; Chen et 
al., 2003). This disparity in results regarding the HER-2/
neu overexpression is related to clinicopathological 
parameters of OSCC (Craven et al., 1992; Field et al., 
1992; Pardis et al., 2012; Rivière, Becker, and Löning, 
1991). Hence the role of HER-2/neu in carcinogenesis 
of oral squamous cell carcinoma remains controversial. 
The present study aimed to evaluate the expression of 
HER-2/neu in a subset of South-East Asian population 
as data is scarce in such OSCC patients. In the present 
study, only one case (0.72%) showed overexpression 
(2+) with 139 (99.28%) cases showing no significant 
staining of cancer tissue. This is similar to the findings 
of previous studies in discrete populations reporting no 
overexpression of HER-2/neu in OSCC (Angiero et al., 
2008; Ekberg et al., 2005; Pardis et al., 2012; Sardari et 
al., 2012; Shintani et al., 2004). On the other hand, some 
studies have reported the overexpression of HER-2/neu 
suggesting its use as a marker to differentiate healthy 
from cancer tissues (Cavalot et al., 2007; Fonget al., 2008; 
Lebeau et al., 2001). On reviewing the current evidence, it 
is hypothesized that overexpression of HER-2/neu occurs 
only in a small number of OSCC cases. To support our 
conclusion, we carried out an in-depth analysis of different 
perineural invasion (PNI), lymphovascular invasion 
(LVI), distant metastasis (DM), and stage of the tumor 
were expressed in frequencies and percentages. A chi-
square test was used among different groups to construct 
association. Since tumor size and tumor thickness were 
continuous variables so, Kruskal-Willis and Mann-
Whitney test were used to find the difference in the mean 
ranks of tumor size and thickness. A p-value of less than 
0.05 was regarded as statistically significant.
Results
This cross-sectional study was carried out on 140 
OSCC patients, with 90 (64.3%) males and 50 (35.7%) 
females. Most of the patients (41; 29.3 %) age ranged 
between 49 to 58 years. Buccal mucosa was found to 
be the most common site (69; 49.3%), followed by 
mandible and tongue (24; 17.1%). Most of the tumors 
were moderately differentiated (87; 62.1%) followed 
by poorly differentiated (30; 21.3%) and (23; 17.1%) 
well-differentiated OSCC. Maximum number of patients 
had stage IV tumors (71; 50.7%), followed by stage II (35; 
25.0), stage III (24; 17.1%) and stage I (10; 7.1%) tumors. 
Lymph node metastasis was present in 51.4% (n = 72) 
and absent in 48.5% (n=68) of OSCC patients. The mean 
tumor size was 3.4 ± 1.9 (range 0.5-11cm) with the mean 
tumor thickness of 1.8 mm (range 0.2-11mm). Perineural 
invasion was present in 22.9% and absent in 77.1% of 
OSCC patients. While the lymphovascular invasion was 
present in 8.6% and absent in 91.4% of OSCC patients. 
Distant metastases (Stage IVC) was found in only 8 
(5.7%) OSCC patients.
HER-2/neu was found to be positive (2+) in one case 
of OSCC, with weak to moderate complete membrane 
staining observed in >10% of the tumor cells (Figure 
1). The remaining 139 cases were HER-2/neu negative 
(Figure 2). FISH analysis of Her2/neu positive case also 
showed gene amplification (HER2-neu/ CEp 17 = 225/33 
= 7.2) (Figure 3).
Discussion
The immunohis tochemica l  express ion  of 
Figure 1. Immunohistochemical Staining for OSCC- 
Showing Weak to Moderate Dark Brown Membranous 
Staining (arrow) of HER-2/neu (2+) 200X. Inset in shows 
positive control for Her2/neu expression (invasive ductal 
carcinoma of breast, 400X). (Case. No. 90)
Figure 2. Immunohistochemical Expression of HER-
2/neu in OSCC Showing Negative Expression (200X) 
(arrows) (Case. No.68).  
Figure 3. Representative FISH Image of OSCC Showing 
Interphase Index Using HER-2/CEP 17 Dual-Color 
Probe. Her2 gene amplification is seen. Gene signals are 
red- labeled, CEP 17 signals are green-labeled (arrow) 
(Case. No.90).
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studies by recording the total number of cases studied, the 
number of cases showing positive outcomes and intensity 
of positive expression (1+, 2+, 3+ and 4+). According 
to CAP guidelines for HER-2/neu immunostaining, an 
outcome of 3+ is regarded as overexpression of protein 
(Richardson et al., 2012; Wolff et al., 2007). Many 
of the authors including Chen et al., (2003) reported 
overexpression of HER-2/neu in 41% (n=59) cases, 
however failed to mention the scores. Similarly, Azemar 
et al., (2000) reported the overexpression of HER-2/neu 
in 58% of cases (n=45) but did not report the scores. 
On the other hand, Fong et al (33) reported HER-2/
neu overexpression in 50% of his cases (12 cases 1+, 
and 3 cases 2+), while Seifi et al., (2009) reported 
overexpression of HER-2/neu in 72% of OSCC cases (5 
cases 1+, 8 cases 2+). However, in both these studies, none 
of the cases were 3+ which is regarded as overexpression. 
Dragomi et al., (2012) reported five cases as 3+ (n= 44) 
while Schartinger et al., (2009) (n=116), (Bernardes, et 
al., 2010) (n=46) and Khan et al., (2002) (n=26) reported 
only one case with 3+ overexpression. 
In a study by Wilkman et al., (1998) only 11 cases 
of squamous cell carcinoma reported intense staining of 
her2/neu in the poorly differentiated epithelium. While 
in the present study, no difference in expression of 
HER-2/neu was seen among different histological grades 
of OSCC (p=0.23). Beckhardt et al., (1995) revealed 
only 6 of 38 (16%) OSCC tissue sections with HER-2 
oncoprotein overexpression. While (Stoicanescu et al., 
2013) reported overexpression of HER-2/neu in only 25% 
of cases among which, 5.2% were 1+, 14.7% were 2+ and 
only four cases had 3+ expression. Hanken et al., (2014) 
reported overexpression of HER-2/neu in only 4 cases out 
of 196 (1 case 1+, 2 cases 2+ and 1 case 3+) . They also 
carried our FISH analysis reporting gene amplification in 
6 out of 207 cases, suggesting that these cases can benefit 
from antiHER-2 therapy. Birkeland et al., (2016) reported 
overexpression in only 2 out of 92 cases of OSCC. Both 
the authors concluded that despite this low Her2/neu 
overexpression of only 1 – 2%, those few patients could 
benefit from anti HER-2 therapy, thus highlighting the 
role of this receptor in personalized medicine.
In multiple studies conducted to study HER-2/
neu expression in OSCC, purely membranous staining 
(Craven et al., 1992; Hoffmann et al., 2001; Khademi et 
al., 2002) or cytoplasmic staining (Angiero et al., 2008; 
Craven et al., 1992; Field et al., 1992; Khademi et al., 
2002), and mixed membranous-cytoplasmic staining 
(Bei et al., 2004; Craven et al., 1992; Ibrahimet al., 1997; 
Rautava et al., 2008; Xia et al., 1997; Xia et al., 1999) have 
been reported. In squamous cell carcinoma, cytoplasmic 
staining is commonly reported but according to Cavalot et 
al., (2007) it is said to be a technical artifact due to cross-
reactive antibodies possibly with keratin or during antigen 
retrieval process. For better, authentic and more reliable 
results we considered purely membranous staining as 
positive for the cases in the present study.
Literature has shown inconsistency among correlation 
of HER-2/neu with clinicopathological parameters of oral 
squamous cell carcinoma irrespective of overexpression 
of HER-2/neu. In the present study, there was no 
association of HER-2/neu expression with any of the 
clinicopathological parameters. This is similar to other 
studies (Cavalot et al., 2007; Khan et al., 2002) with no 
significant association between HER-2/neu positivity 
with age, sex, race, tumor site, tumor stage, grade, and 
recurrence. A study by Fong et al., (2008) reported 
overexpression of HER-2/neu in stage IV OSCC as 
compared to stage I-III OSCC cases. This is in contrasts 
with the present study showing no significant association 
with tumor stage (p=0.388). Therefore, researchers like 
Riviere et al., (1991), Field et al., (1992), Khan et al., 
(2002), Ekberg et al., (2005) and Angiero et al., (2008) did 
not suggest HER-2/neu as a prognostic factor or treatment 
indicator in OSCC patients. A possible explanation 
for disparity among study outcomes is a lack of 
standardization of the assay methods (the direct, indirect 
technique of immunohistochemistry) and use of different 
techniques (immunosorbent assay, radioimmunoassay, 
IHC). A careful review of studies showed a variation 
in the type of antibody used that recognize different 
epitopes of protein (Clone CerbB2, CB11, ICR1b, 
polyclonal DAKO, monoclonal enzyme), in addition to 
lack of specific criteria for positive staining of HER2/neu 
protein (membrane and/ or cytoplasmic). In particular, the 
significance of cytoplasmic staining is the most widely 
debated question. Gender variation and differences in the 
site of primary tumors are also considered to contribute to 
this disparity in results (Cavalot et al., 2007).
The present study supports the idea that, despite 
low Her2/neu overexpression (1-2 %), patients with 
positive results could benefit from anti-cancer/anti-Her2 
therapy. As oral cavity is part of gastrointestinal 
tract, Her2 testing on gastric biopsies should be 
investigated and optimized for immunohistochemical 
scoring in OSCC tissues employing future studies. 
Further studies are recommended to establish standard 
immunohistochemistry staining protocols to aid uniform 
reporting of protooncogene in OSCC.
In conclusion, the study showed disparity in the 
expression of HER-2/neu in OSCC which is due to 
multiple reasons. Therefore therapy against HER-2/neu 
in OSCC is debatable. 
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